Fertility services provider Monash IVF Group (ASX: MVF) says it is on a path back to stability after a tumultuous year marked by an IVF laboratory incident that triggered executive turnover, dented patient confidence and weighed on earnings.
The company reported first-half FY26 revenue of $137.9 million, down 1.8% on the prior corresponding period, and underlying net profit after tax (NPAT) of $10.4 million. The result was in line with guidance issued in November and underpins full-year underlying NPAT guidance of $20 million.
The numbers represent a stabilisation after a difficult 2025, when an IVF mishap — widely reported in metropolitan media — led to intense scrutiny of clinical governance and prompted changes in senior leadership. The episode saw a drop in domestic stimulated cycles and softer new patient registrations as some prospective parents deferred treatment.
Since then, the board has reshaped the executive team and sought to rebuild trust in the group’s clinical processes. Newly appointed chief executive Dr Victoria Atkinson said her immediate focus was on “clinical and operational excellence” and delivering a consistent, high-quality patient experience.
“Monash IVF has a strong clinical heritage, a dedicated team of specialists and embryologists, and a trusted national footprint,” Dr Atkinson said. “We remain committed to executing our strategy and delivering sustainable value for shareholders.”
Operationally, there are signs of resilience. The group maintained sector-leading clinical pregnancy rates, with a 0.6 percentage point increase in pregnancy rates per embryo transferred for women aged under 43, reaching 40.7% for the nine months to September 2025. That compares with 32.6% in calendar 2018, underscoring longer-term gains in laboratory performance.
Monash IVF performed 5,163 stimulated cycles in Australia during the half and retained its position as the nation’s second-largest IVF provider with a 19% market share. It remains the only operator with clinics in all mainland capital cities, a footprint management believes is a competitive advantage as patient volumes recover.
Domestic stimulated cycles fell 11.7% compared with the prior corresponding period, reflecting lingering reputational impacts and broader cost-of-living pressures. However, international stimulated cycles rose 6.9%, and higher-value genetic testing cycles (PGT-M) increased 26%, partly offsetting softer volumes in standard treatments.
Earnings before interest, tax, depreciation and amortisation (EBITDA) came in at $30.2 million, down from $35.6 million a year earlier, with margins pressured by lower volumes and the decision not to raise IVF patient prices in Victoria, New South Wales and Queensland during FY26. Even so, the board declared a fully franked interim dividend of 1.2 cents per share, signalling confidence in cash flow.
The balance sheet remains geared but manageable. Net debt rose to $96.2 million at December 31, with a net leverage ratio of 2.0 times — comfortably below banking covenant limits. Capital expenditure of $10 million in the half reflects a near-complete infrastructure upgrade, including a new Brisbane clinic due in the fourth quarter of FY26.
Emily Maxwell is a business writer at The Sentiment with interest in the tech, fintech and retail industries.
Latest posts by Emily Maxwell (see all)
- Boom in refurbished tech adoption drives Harris Technology into profitability - February 26, 2026
- Monash IVF charts steady recovery after turbulent year - February 26, 2026
- Tabcorp delivers double-digit earnings growth as cost cutting offsets soft sports wagering - February 25, 2026
Leave a Comment
You must be logged in to post a comment.